Abstract
Evaluation of biological agents targeted at early-stage disease
Highlights
Recent pharmacodynamic studies of epidermal growth factor receptor (EGFR) inhibitors have provided some clues that might be of clinical use, as this approach can be potentially applied to other novel compounds and/or combinations
Similar results were reported by Polychronis and coworkers [11] in effect in oestrogen receptor (ER)-positive/EGFR-positive newly diagnosed breast cancers treated for 6 weeks with neoadjuvant gefitinib
Because phosphorylation of this site is regulated mainly by mitogen-activated protein kinase (MAPK) [12], these findings provide evidence of operative crosstalk between ER and ErbB receptor signalling early in the natural history of hormone-dependent breast cancer
Summary
Recent pharmacodynamic studies of epidermal growth factor receptor (EGFR) inhibitors have provided some clues that might be of clinical use, as this approach can be potentially applied to other novel compounds and/or combinations. Treatment-induced tumour cell apoptosis, as measured by cleaved caspase-3 immunohistochemistry 1 week after administration of the antihuman epidermal growth factor receptor (HER)-2 monoclonal trastuzumab, correlates with clinical response of HER-2 overexpressing breast cancers [5].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
